HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.

October 16, 2026

Vol.52 No.38

Cancer Policy

FDA’s expedited IND pilot aims to shorten the timeline between drug development and first-in-human clinical trials

FDA announced the final design of the Expedited Investigational New Drug Pilot.

September 18, 2026

Vol.52 No.34

Clinical Roundup

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

Why do signaling proteins called interferons, which recruit the immune system to attack cancer cells, start helping the tumor grow rather than shrink when they linger too long?

September 18, 2026

Vol.52 No.34

In Brief

Weizhou Zhang named co-leader of expanded immuno-oncology and microenvironment research program at UF Health Cancer Institute

Weizhou Zhang, who is leading research on cancer immunotherapeutics and basic mechanisms of cancer immunology, was named co-leader of the UF Health Cancer Institute’s Immuno-Oncology and Microenvironment research program.

September 11, 2026

Vol.52 No.33

HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers

YOU MAY BE INTERESTED IN

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

FDA’s expedited IND pilot aims to shorten the timeline between drug development and first-in-human clinical trials

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

Weizhou Zhang named co-leader of expanded immuno-oncology and microenvironment research program at UF Health Cancer Institute

Renew today!

Subscriber content

Never miss an issue!

Login